■ Iantrek announced that 12-month clinical results of a novel biostenting procedure using the company’s microsurgical instrumentation have been published in the British Journal of Ophthalmology. The research, which was led by glaucoma specialists Ike Ahmed, MD; Robert Weinreb, MD; and Sean Ianchulev, MD, MPH, reports on the long-term outcomes from the use of scleral allograft biotissue to stent the supraciliary space and enhance uveoscleral outflow. In the study, microinterventional supraciliary stenting achieved a sustained IOP reduction over 12 months — close to 40% reduction from a medicated baseline of 24.2±6.9 mmHg to 14.6±3.2 mmHg. Additionally, 80% of the patients achieved more than a 20% reduction in IOP, and the number of glaucoma medications required was reduced by 62%. The biostenting approach leverages a highly permeable, conforming scleral allograft biotissue delivered using Iantrek’s proprietary microsurgical instrumentation.